PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Dillon, M.T., Boylan, Z., Smith, D. et al. (10 more authors) (2018) PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clinical and Translational Radiation Oncology , 12. pp. 16-20. ISSN 2405-6308

Abstract

Metadata

Authors/Creators:
  • Dillon, M.T.
  • Boylan, Z.
  • Smith, D.
  • Guevara, J.
  • Mohammed, K.
  • Peckitt, C.
  • Saunders, M.
  • Banerji, U.
  • Clack, G.
  • Smith, S.A.
  • Spicer, J.F.
  • Forster, M.D.
  • Harrington, K.J.
Copyright, Publisher and Additional Information: PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
Keywords: Phase I; Radiosensitization; ATR inhibition; DNA damage response; Clinical trial
Dates:
  • Accepted: 6 June 2018
  • Published (online): 8 June 2018
  • Published: 1 August 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 25 Feb 2019 11:18
Last Modified: 25 Feb 2019 12:22
Published Version: https://doi.org/10.1016/j.ctro.2018.06.001
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.ctro.2018.06.001
Related URLs:

Export

Statistics